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Background: Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial 
repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and 
function so promoting vascular complications.
Aim of the Study: This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase 
the number of EPCs and restores their function.
Methods: Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of 
an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without 
diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had 
a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34＋/KDR＋) in comparison to healthy controls (p＜0.01).
Results: The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase 
of EPC levels (mean of 18%, p＜0.04 vs. baseline) and number of EPCs CFUs (p＜0.05 vs. baseline).
Conclusion: This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, 
most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number 
and in bioactivity.
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Introduction 
  EPCs are bone marrow-derived cells mobilized from the 
vascular niche to the peripheral circulation in response to 
tissue injury (1-5). Circulating EPCs home to damaged or 
ischemic microcirculatory beds where they actively partic-
ipate in endothelial repair and neovascularization (6-8). 
Insulin resistance and hyperglycemia in patients with DM 
result in endothelial dysfunction by promoting the pro-
gression of atherosclerosis and cardio circulatory compli-
cations (9-12). It is well established that DM is associated 
to a reduced availability and downregulation of EPCs with 
an altered pattern of plasma growth factors and anti-oxi-
dant gene expression (13-18). Interestingly, EPCs can be 
reduced in pre-diabetic states (impaired fasting glucose 
and impaired glucose tolerance) with further significant 
decrease at the time of clinical diagnosis of diabetes (19). 
The detrimental effects of DM on EPC number and func-
tion can impair vascular repair and regenerative activity 
and lead to vascular complications and worse clinical 
prognosis (20, 21). The definitive mechanisms responsible 
for the effects of hyperglycemia on EPCs needs to be 
elucidated. Decreased availability and down regulation of 
EPCs can occur as dysfunction in their mobilization, dif-
ferentiation, migration and adhesion secondary to in-
creased oxidative stress, reduced nitric oxide availability, 
altered secretion functions and derangement of intra-
cellular signal pathways such mitogen-activated protein 
kinase (MAPK)/c-Jun N-terminal kinase (JNK) and phos- 
phoinositide 3-kinase pathways (11, 22-26). When diabetic 
patients are compared to the group of control subjects, 
glycemic control exerts a positive influence on clinical in-
cidence of ischemic events, cardiovascular accidents, and 
micro or macroangiopathies (18).
  In this study, we analyzed the features of EPCs in se-
vere Type 2 DM and the possible reversible effects of gly-
cemic control. In particular, we evaluated whether a peri-
od of intensive glycemic control (three months) can influ-
ence the number and dynamics of mobilization of EPCs.
Materials and Methods
  Type 2 DM patients and healthy controls between 50 
and 85 years of age were eligible for inclusion in the study 
and enrolled from outpatient clinic basis. The overall risk 
factor load of an individual patient using a risk factor 
score including age above 40 years, male gender, hyper-
tension, smoking, family history for cardiovascular heart 
diseases, and hypercholesterolemia, were calculated. Pa-
tients with type 2 DM (mean age 58.2±5.4 years, 25.6% 
women, disease duration of 15.4±6.3 years) had a baseline 
HgA1c of 8.7±0.5%. Exclusion criteria were the presence 
of acutely decompensate heart failure; a history of leuco-
penia, thrombocytopenia, or severe hepatic and renal dys-
function, evidence for inflammatory or malignant disease; 
or unwillingness to participate. Glicemic control was ach-
ieved in Type 2 diabetic group with a balanced dietary 
regimen, as previously described in detail (27). Diabetic 
patients were subjected to dietary evaluation (by food 
questionnaire) during the screening visit and monthly 
during the severe glucose control. Diabetic subjects were 
encouraged to control the body weight during the study 
and dietary regimen was provided. The proposed diet had 
a composition that was on average 27∼28% fat (＞80% 
in the form of monoinsatured fatty acids), 12∼14% pro-
teins and 52∼58% carbohydrate (75% in the form of com-
plex carbohydrate) while the colesterol intake was less 
than 210 mg day−1. Daily fibre assumption was greater 
than 58 mg. The study protocol was approved by the eth-
ics review board and was conducted in accordance with 
the Declaration of Helsinki. Written informed consent was 
obtained from each patient. 
Study protocol for isolation and count of EPCs 
  Mononuclear cells were isolated by density gradient 
centrifugation with Biocoll (Biochrom, Berlin, Germany) 
from 20 mL of venous blood as previously described in 
detail (4, 28). Briefly, after isolation, 4×106 mononuclear 
cells were placed on 24-well culture dishes blankets with 
human fibronectin (Sigma-Aldrich, Munich, Germany) 
and kept in endothelial basal medium (Cambrex, Walker-
ville, MD, USA) enriched with endothelial growth me-
dium and 20% fetal calf serum. After the 4th day in cul-
ture, non-engrafted cells were detached by thorough wash-
ing with phosphate-buffered saline (PBS).
Characterization of late EPCs
  Was assessed the uptake of 1,1'-dioctadecyl-3,3,3',3'-tet-
ramethylindocarbocyanine-labeled acetylated low-density 
lipoprotein (DiLDL) by cells as described in detail (4, 28). 
Incubation of cells with DiLDL (2.4 μg/mL) was perfor-
med at 37oC for 1 hour. Then, cells were fixed with 2% 
paraformaldehyde for 10 min and incubated with fluo-
rescein-5-isothiocyanate (FITC)-labeled agglutinin I (lectin, 
10 μg/mL; Sigma-Aldrich, Milan, Italy) for 1 hour. Dual- 
staining cells positive for both lectin and DiLDL were con-
sidered as EPCs. The endothelial features were additionally 
documented by flow cytometry analysis of vascular endo-
thelial growth factor receptor 2 (KDR) and von Willebrand 
factor (4, 28). The number of EPCs was evaluated by count-
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Table 1. Baseline characteristics of the study population
Healthy 
controls
Type 2 diabetic 
patients
p-value1
n 17 45
Age (years) 54.85±4.5 58.2±5.4 NS
Gender (male/female) 12/5 33/12 NS
LVEF (%) ND 46.9±6.4 ND
NYHA functional class 0 0 0
Hypertension (number) 2 10 0.01
Smoking (number) 10 6 NS
Family history for CHD 
(number)
5 11 0.05
LDL cholesterol 112.5±13 136±26 0.01
Statin (number) 0 22
ACE-I/ARB (number) 2 18 0.01
Beta-blockers (number) 2 7 0.05
Diuretics (number) 0 11 0.01
HsCRP (mg/dL) 0.05±0.08 0.13±0.04 0.05
BaselineHbA1c 3.1±0.06 8.7±0.5 0.01
After glycemic control 
HbA1c
6.2±0.3
Data are presented as mean±SD. ACE-I/ARB: angiotensin-convert-
ing enzyme inhibitors/angiotensin II receptor blockers; hsCRP: 
high-sensitivity C-reactive protein; CHD: coronary heart disease; 
LVEF: left ventricular ejection fraction; LDL: low density lipopro-
teins; NYHA: New York Heart Association; ND: not determined; 
NS: non-significant. 
1Comparison-wise p value for comparison of healthy controls and 
type 2 diabetic patients.
ing carefully selected high-power fields (4, 28).
Measurement of functional capacity of EPCs 
  Isolated EPCs were separated using 1 mmol/L ethyl-
enediaminetetraacetic acid in PBS (pH 7.4), harvested by 
centrifugation, resuspended in 500 μL endothelial basal 
medium, counted, and placed in the upper chamber of a 
modified Boyden chamber (2×104 cells; BD Bioscience, 
Milan, Italy) as described in our previous studies (4, 28). 
For identification, cell nuclei were marked with 4',6'-dia-
midino-2-phenylindole. Cells migrating into the lower 
chamber were quantified in several random microscopic 
fields (4, 28).
Bone marrow mononuclear cells
  Bone marrow-derived mononuclear cells (BM-MNCs) 
were isolated from bone marrow aspirates by density gra-
dient centrifugation. After two washing procedures, we per-
formed a cell suspension using an X-vivo medium (Cam-
brex, Walkerville, MD, USA) with heterogeneous cell pop-
ulations including hematopoietic progenitor cells (4, 28). 
Flow cytometry analysis of BM-MNCs
  For the identification of hematopoietic stem/progenitor 
cell populations cells were added with conjugated anti-
bodies against human CD45 (mouse FITC-labeled; BD 
Pharmingen, Milan, Italy), human CD34 (FITC-labeled 
and allophycocyanin-labeled; BD Pharmingen) and hu-
man CD133 (allophycocyanin-labeled; Miltenyi Biotec, 
Bologna, Italy) (4, 28). 
Colony-forming unit assay
  The BM-MNCs (1×105 per well) were founded in meth-
ylcellulose plates (Methocult GF H4535, Stem Cell Tech-
nologies, Milan, Italy) enriched with stem cell factor, gran-
ulocyte colony-stimulating factor, granulocyte-macrophage 
colony-stimulating factor, IL-3, and IL-6. Plates were ana-
lyzed under phase-contrast microscopy, and granulocyte- 
macrophage colony-forming units (CFU-GM, colonies ＞50 
cells) were counted at the 14th day of incubation (4, 28).
Measurement of High-sensitivity C-reactive protein 
levels
  High-sensitivity C-reactive protein from serum of type 
2 DM patients and healthy controls was measured by 
means of particle-enhanced immunonephelometry (Dade 
Behring, Marburg, Germany) as previously described (4).
Statistical analyses
  The non-parametric Mann-Whitney U test was used to 
assess differences between two groups. Categorical varia-
bles were compared by the chi-square test or the Fisher 
exact test. Bivariate correlation was calculated by Pearson 
correlation. A linear regression model was used to evaluate 
independent predictors. If not stated otherwise, data are 
expressed as mean±SD. Statistical significance was as-
sumed at p≤0.05. All statistical analyses were performed 
using SPSS for Windows version 12.0 (SPSS Inc., Chicago, 
IL, USA).
Results 
  The characteristics of the study population are de-
scribed in Table 1. The two populations (healthy controls 
and Type 2 DM patients at baseline) were comparable for 
age, gender, for smoking activity and for NYHA functional 
class. Significantly differences were assessed for number 
of hypertensive subjects, family history for CHD, for LDL 
cholesterol, and for use of drugs as statins, ACE-I/ARB, 
beta-blockers and diuretics in the DM group. Finally, 
High-sensitivity C-reactive protein was higher in Type 2 
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Table 2. Linear regression analysis: depending variable of endothelial progenitor cell number
Total population 
(n=62)
Type 2 diabetic patients baseline Type 2 diabetic patients after glycemic control
p-value 
univariate
r 
univariate
p-value 
multivariate
p-value 
univariate
r 
univariate
p-value 
multivariate
Age 0.006 −0.377 0.074
HsCRP ＜0.05 −0.358 0.112 ＜0.05 −0.263 0.228
Family history for 
CHD (number)
0.134 −0.114 0.436
Hypertension 0.782 −0.093 0.512
Diabetes ＜0.05 −0.543 0.042 ＜0.05 −0.463 0.058
Smoking 0.086 −0.303 0.479
hsCRP: high-sensitivity C-reactive protein.
Fig. 1. Number of EPCs positive to FACS and  EPCs positive to
chemotaxic assay for VEGF-A in healthy group vs type 2 DM pa-
tients pre- and after glycemic control.
DM patients at baseline compared to healthy control 
group. 
  As shown in Table 2, in Type 2 DM baseline, the main 
determinants of EPC cell number on univariate analysis 
were advanced age, elevated serum levels of hs-CRP and 
the status of diabetes. When we considered the multi-
variate analysis, only the presence of Type 2 DM was an 
independent predictor of reduced numbers of circulating 
EPCs, whereas all other parameters lost predictive power 
(Table 2). Thus, in our experimental conditions, Type 2 
DM itself was an independent determinant of circulating 
EPC levels. The numbers of hematopoietic progenitor 
cells, by which the circulating EPCs presumably rise, were 
determined by the expression of the marker protein CD34 
by flow cytometry analysis. EPC levels (CD34＋/KDR＋) 
were lower in Type 2 DM patients in comparison to 
healthy controls (64±13 vs 104±21, p＜0.01). Relevantly, 
the number of EPCs in patients with Type 2 DM in-
creased after three months of glycemic control (64±13 
baseline vs 78±11 post glycemic control, p＜0.04) (Fig. 1). 
However, the difference in EPC level (CD34＋/KDR＋) 
(FACS analysis) between the healthy controls and Type 
2 DM patients, also after the glycemic control, remained 
statistically significant (p＜0.05) (Fig. 1).
Functional capacity of circulating EPCs at baseline and 
after glycemic control
  The functional capacity of circulating EPCs was as-
sessed by measuring their migratory attitude in response 
to VEGF. EPCs derived from patients with Type 2 DM 
showed a significant impaired migratory capacity assessed 
by EPC chemotaxis assay toward VEGF-A compared with 
EPCs derived from healthy controls (Fig. 1, p＜0.01 vs 
controls). After glycemic control, migratory capacity sig-
nificantly improved compared to pre-glycemic control (p
＜0.05) but was still significantly lower than in healthy 
controls. In Type 2 DM patients, on univariate analysis, 
the main determinants of EPC functional capacity at base-
line were advanced age, elevated serum levels of hs-CRP, 
the family history for CHD and the status of diabetes 
(Table 3). After glycemic control, the only determinant 
was the elevated levels of hs-CRP. However, on multi-
variate analysis, only the presence of Type 2 DM was an 
independent predictor of reduced migratory capacity of 
EPCs (Table 3). Taken together, Type 2 DM is associated 
with a reduced number of circulating and functional im-
pairment of EPCs. 
Functional capacity of BM-MNCs
  The expertise of progenitor cells in the BM aspirates was 
determined by measuring CFU-GM activity. The BM- 
MNCs derived from Type 2 DM patients showed a sig-
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Table 4. Linear regression analysis: depending variable of colony-forming unit–granulocyte-macrophage
Total population 
(n=62)
Type 2 diabetic patients baseline Type 2 diabetic patients after glycemic control
p-value 
univariate
r 
univariate
p-value 
multivariate
p-value 
univariate
r 
univariate
p-value 
multivariate
Age 0.006 0.293 ND
HsCRP ND
Family history 0.483 −0.082 ND
Hypertension 0.563 0.032 ND
Diabetes 0.106 −0.301 0.05 0.156 −0.286 0.05
Smoking 0.364 −0.186 ND
Sum risk factors 0.036 −0.307 ND
CD34＋CD45＋ cells 0.023 0.286 ND
CD34＋CD133＋ cells 0.037 0.304 ND
Adjusted R2 0.260 0.189
Significance (ANOVA) 0.01 0.01
hsCRP: high-sensitivity C-reactive protein.
Table 3. Linear regression analysis: depending variable of endothelial progenitor cell function (migratory capacity)
Total population 
(n=62)
Type 2 diabetic patients baseline Type 2 diabetic patients after glycemic control
p-value 
univariate
r 
univariate
p-value 
multivariate
p-value 
univariate
r 
univariate
p-value 
multivariate
Age 0.004 −0.393 0.040
HsCRP 0.031 −0.384 0.526 0.009 0.433 0.402
Family history for 
CHD (number)
0.028 −0.402 0.035
Hypertension 0.768 −0.012 ND
Diabetes 0.108 −0.268 0.054 0.092 −0.319 0.048
Smoking 0.682 0.058 ND
hsCRP: high-sensitivity C-reactive protein.
nificantly reduced number of CFU-GM compared to BM- 
MNCs from healthy controls (51±19 vs 84±32 number of 
colonies per 105 cells, p＜0.02 vs controls). The number 
of EPC CFUs also increased significantly after glycemic 
control (65±14 number of colonies per 105 cells, p＜0.05 
vs baseline). In Type 2 DM patients at baseline, on uni-
variate analysis, the main determinants of CFU-GM were 
advanced age, sum risk factors, number of CD34＋CD45＋ 
and CD34＋CD133＋ cells (Table 4). However, on multi-
variate analysis, only the presence of Type 2 DM was an 
independent predictor of reduced numbers of CFU-GM at 
baseline and after glycemic control.
Discussion 
  This study confirms that EPC number and bioactivity 
are reduced in patients with Type 2 DM and, most im-
portantly, shows that an intensive glycemic control in the 
same group of patients can restore EPC number with less 
pronounced but still significant improvement in their 
function. There is a wide evidence on the key role of circu-
lating EPCs in the maintenance of endothelial integrity, 
function and angiogenesis (29, 30), with growing interest 
on their use as a novel therapy for cardiovascular diseases 
(2, 7, 31). DM is associated to decreased EPC level and 
function leading to a rapid development of atherosclerosis, 
microangiopathies and cardiovascular accidents (13-19, 25, 
26, 32, 33). EPCs can be considered biological markers in 
the DM patients and prognostic indicators of future car-
diovascular complications in these subjects (33-37). Ex-
haustion of the pool of progenitor cells in the bone mar-
row, the impaired functional capacity within the bone 
marrow, the reduced mobilization, survival and/or differ-
entiation of EPCs could account for the lower circulating 
EPC number in DM patients (2, 7, 37). Previous studies, 
showed that DM patients with good glycemic control have 
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a higher circulating EPC number and a better function 
compared to DM patients with inadequate glycemic con-
trol (18, 19, 32). Our data demonstrated that a relatively 
short period of intensive glycemic control in Type 2 DM 
patients can reverse the tendency to decline of EPC level 
and positively affect EPC function. We showed a close re-
lationship among glycemic control, number and migratory 
response of EPCs in these patients. We adopted a stand-
ardized protocol, which showed a high capacity to detect 
specifically EPC subpopulations (late EPCs) (4, 28). How-
ever, we advocate that further standardization of labo-
ratory techniques for the detection of EPCs as FACS pro-
tocols could better compare different data concerning sev-
eral studies. Here, we confirm and extend previous ob-
servation that DM patients show a functional impairment 
of EPCs both in the BM as well as in peripheral blood 
as circulating progenitors. A relevant data was that, after 
adjusting for other cardiovascular risk factors and medi-
cations, the glycemic control was identified as an indepen-
dent variable for EPC count and function. On the other 
hand, the circulating EPC number and bioactivity in DM 
patients after glycemic control did not reach the EPC level 
of healthy controls as observed by previous studies (32). 
Interestingly, in type 2 DM patients, the glycemic control 
has a greater impact on the number of circulating EPC 
with respect to the increase of CFU. This data suggests 
that EPC migratory response is less restored in compar-
ison to EPCs levels. We believe that these results need to 
be confirmed in larger cohorts of diabetic subjects consid-
ering also extended periods of glycemic restriction. Our 
results indicate that in Type 2 DM patients, glucose con-
trol may be considered a mechanism to preserve EPC pool 
inverting the diabetic degenerative pattern coupled with 
endothelial dysfunction, progression of atherosclerosis and 
cardio circulatory complications. 
  This study is only an observational research. Additional 
investigation is needed to explore the mechanism of the 
increase of EPCs after glucose control. Furthermore, tak-
ing into consideration the different treatment categories 
used by enrolled patients, we suggest randomized-con-
trolled clinical trials focusing on the effect of single an-
ti-diabetic drugs on EPC pool (16, 38, 39). Further re-
searches are needed to validate our findings in patients 
subjected to different pharmacological treatments in addi-
tion to the dietary regimen.
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